Validity of the Chronic Airways Assessment Test (CAAT) in asthma, asthma+COPD and COPD in NOVELTY
The CAAT demonstrated consistent cross-sectional validity across asthma and/or COPD, making it applicable for assessing health status in these conditions in clinical practice and research.
Authors
- Paul Jones (ORCID: https://orcid.org/0000-0001-6087-9182)
- Christina Keen (ORCID: https://orcid.org/0000-0003-4979-6073)
- Laura Belton
- Helen Kathryn Reddel (ORCID: https://orcid.org/0000-0002-6695-6350)
- Hana Müllerová (ORCID: https://orcid.org/0000-0002-0949-0101)
- Alberto Papi (ORCID: https://orcid.org/0000-0002-6924-4500)
- Erin Tomaszewski (ORCID: https://orcid.org/0000-0003-3995-3127)
- Barry J. Make (ORCID: https://orcid.org/0000-0003-4349-8745)
- Pierre‐Régis Burgel (ORCID: https://orcid.org/0000-0003-0903-9828)
- Rod Hughes
Institutions
- AstraZeneca (United Kingdom) (GB)
- Inserm (FR)
- University of Ferrara (IT)
- Université Paris Cité (FR)
- National Jewish Health (US)
- AstraZeneca (South Korea) (KR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Jones Institute (US)
- AstraZeneca (France) (FR)
- Royal Mail Group (United Kingdom) (GB)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Italy) (IT)
- Institut Cochin (FR)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- University of Colorado Denver (US)
- Macquarie University (AU)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1183/23120541.01359-2024
- Citations
- 1
- Primary Topic
- Injury Epidemiology and Prevention
- Type
- article
- Field-Weighted Citation Impact
- 1.88
Funders
- AstraZeneca